CB2 Receptor Agonists Protect Human Dopaminergic Neurons against Damage from HIV-1 gp120

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Hu, Shuxian ^a   Sheng, Wen S ^a   Rock, R Bryan ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; DOPAMINE TRANSPORTER; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BENZOXAZINE DERIVATIVE; CYTOKINE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; SUPEROXIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN REGION; CELL CULTURE; CELL LOSS; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; GLIA CELL; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOREACTIVITY; LIPID PEROXIDATION; MESENCEPHALON; MICROGLIA; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; SUPERNATANT; BIOSYNTHESIS; CELL MOTION; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

APOPTOSIS; BENZOXAZINES; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; HIV ENVELOPE PROTEIN GP120; HUMANS; LIPID PEROXIDATION; MESENCEPHALON; MICROGLIA; MORPHOLINES; NAPHTHALENES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB2; RECOMBINANT PROTEINS; SUPEROXIDES;

EID: 84885745942     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077577     Document Type: Article

References (130)

1. United Nations Program on HIV/AIDS (UNAIDS) (2011)/World Health Organization Report on the global AIDS epidemic. Geneva: U.N. AIDS. p. pp. 2011.
2. Boissé L, Gill MJ, Power C, (2008) HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 26: 799-819. doi:10.1016/j.ncl.2008.04.002. PubMed: 18657727.
3. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE, (2005) Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 64: 529-536. PubMed: 15977645.
4. Clements JE, Li M, Gama L, Bullock B, Carruth LM, et al. (2005) The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11: 180-189. doi:10.1080/13550280590922829. PubMed: 16036796.
5. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16. doi:10.1007/s13365-010-0006-1. PubMed: 21174240.
6. McArthur JC, Brew BJ, Nath A, (2005) Neurological complications of HIV infection. Lancet Neurol 4: 543-555. doi:10.1016/S1474-4422(05)70165-4. PubMed: 16109361.
7. Nath A, Sacktor N, (2006) Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19: 358-361. doi:10.1097/01.wco.0000236614.51592.ca. PubMed: 16914973.
8. Chao CC, Hu S, Peterson PK, (1995) Modulation of human microglial cell superoxide production by cytokines. J Leukoc Biol 58: 65-70. PubMed: 7616108.
9. Cosenza MA, Zhao ML, Si Q, Lee SC, (2002) Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 12: 442-455. PubMed: 12408230.
10. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, et al. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093. doi:10.1126/science.3016903. PubMed: 3016903.
11. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB, (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83: 7089-7093. doi:10.1073/pnas.83.18.7089. PubMed: 3018755.
12. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, et al. (2004) Role of microglia in central nervous system infections. Clin Microbiol Rev 17: 942-964. doi:10.1128/CMR.17.4.942-964.2004. PubMed: 15489356.
13. Rock RB, Peterson PK, (2006) Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 1: 117-126. doi:10.1007/s11481-006-9012-8. PubMed: 18040778.
14. D'Aversa TG, Eugenin EA, Berman JW, (2005) NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J Neurosci Res 81: 436-446. doi:10.1002/jnr.20486. PubMed: 15954144.
15. Gendelman HE, editor (2005) The Neurology of AIDS. Oxford; New York: Oxford University Press. 829 pp.
16. Ghorpade A, Persidsky Y, Swindells S, Borgmann K, Persidsky R, et al. (2005) Neuroinflammatory responses from microglia recovered from HIV-1-infected and seronegative subjects. J Neuroimmunol 163: 145-156. doi:10.1016/j.jneuroim.2005.01.022. PubMed: 15869805.
17. González-Scarano F, Martín-García J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81. doi:10.1038/nri1527. PubMed: 15630430.
18. Kaul M, Lipton SA, (2006) Mechanisms of Neuroimmunity and Neurodegeneration Associated with HIV-1 Infection and AIDS. J Neuroimmune Pharmacol 1: 138-151. doi:10.1007/s11481-006-9011-9. PubMed: 18040780.
19. Kaul M, Zheng J, Okamato S, Gendelman HE, Lipton SA, (2005) HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ 12: 878-92. PubMed: 15832177.
20. Mattson MP, Haughey NJ, Nath A, (2005) Cell death in HIV dementia. Cell Death Differ 12 (Suppl 1):: 893-904. doi:10.1038/sj.cdd.4401577. PubMed: 15761472.
21. Corasaniti MT, Strongoli MC, Piccirilli S, Nisticò R, Costa A, et al. (2000) Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Commun 274: 664-669. doi:10.1006/bbrc.2000.3160. PubMed: 10924334.
22. Kaul M, Lipton SA, (1999) Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 96: 8212-8216. doi:10.1073/pnas.96.14.8212. PubMed: 10393974.
23. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, et al. (1998) Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 95: 14500-14505. doi:10.1073/pnas.95.24.14500. PubMed: 9826729.
24. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, et al. (2001) CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 4: 702-710. doi:10.1038/89490. PubMed: 11426226.
25. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, et al. (1988) Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335: 639-642. doi:10.1038/335639a0. PubMed: 2845276.
26. Garden GA, Budd SL, Tsai E, Hanson L, Kaul M, et al. (2002) Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22: 4015-4024. PubMed: 12019321.
27. Yi Y, Lee C, Liu QH, Freedman BD, Collman RG, (2004) Chemokine receptor utilization and macrophage signaling by human immunodeficiency virus type 1 gp120: Implications for neuropathogenesis. J Neurovirol 10 (Suppl 1):: 91-96. doi:10.1080/jnv.10.s1.91.96. PubMed: 14982745.
28. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, et al. (1993) Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43: 2099-2104. doi:10.1212/WNL.43.10.2099. PubMed: 8413973.
29. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM, (2009) In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63: 181-185. doi:10.1002/syn.20594. PubMed: 19086089.
30. Gelman BB, Spencer JA, Holzer CE, Soukup VM, (2006) Abnormal striatal dopaminergic synapses in national neuroAIDS tissue consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 2: 410-20. PubMed: 18040813.
31. Itoh K, Mehraein P, Weis S, (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (Berl) 99: 376-384. doi:10.1007/s004010051139. PubMed: 10787036.
32. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P, (2002) Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm 109: 399-410. doi:10.1007/s007020200032. PubMed: 11956960.
33. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P, (2002) Parkinsonism in HIV dementia. J Neural Transm 109: 767-775. doi:10.1007/s007020200063. PubMed: 12111466.
34. Nath A, Anderson C, Jones M, Maragos W, Booze R, et al. (2000) Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 14: 222-227. doi:10.1177/026988110001400305. PubMed: 11106300.
35. Paul RH, Brickman AM, Navia B, Hinkin C, Malloy PF, et al. (2005) Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J Neuropsychiatry Clin Neurosci 17: 167-171. doi:10.1176/appi.neuropsych.17.2.167. PubMed: 15939969.
36. Sardar AM, Czudek C, Reynolds GP, (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7: 910-912. doi:10.1097/00001756-199603220-00015. PubMed: 8724671.
37. Silvers JM, Aksenov MY, Aksenova MV, Beckley J, Olton P, et al. (2006) Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J Neurovirol 12: 140-145. doi:10.1080/13550280600724319. PubMed: 16798675.
38. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, et al. (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127: 2452-2458. doi:10.1093/brain/awh269. PubMed: 15319273.
39. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, et al. (2004) Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol (Berl) 107: 216-226. doi:10.1007/s00401-003-0801-3. PubMed: 14712399.
40. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, et al. (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 95: 377-387. doi:10.1111/j.1471-4159.2005.03373.x. PubMed: 16190867.
41. Hu S, Sheng WS, Lokensgard JR, Peterson PK, Rock RB, (2009) Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 15: 401-410. doi:10.3109/13550280903296346. PubMed: 20175694.
42. Jones MV, Bell JE, Nath A, (2000) Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 14: 2709-2713. doi:10.1097/00002030-200012010-00010. PubMed: 11125889.
43. Klein TW, Newton C, Larsen K, Lu L, Perkins I, et al. (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496. doi:10.1189/jlb.0303101. PubMed: 12960289.
44. Cabral GA, Griffin-Thomas L, (2008) Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocrinol Metab Immune Disord Drug Targets 8: 159-172. doi:10.2174/187153008785700118. PubMed: 18782012.
45. Croxford JL, Miller SD, (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55. J Clin Invest 212: 1231-1240.
46. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, et al. (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29: 2177-2186. doi:10.1523/JNEUROSCI.4997-08.2009. PubMed: 19490092.
47. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, et al. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132: 3152-3164. doi:10.1093/brain/awp239. PubMed: 19805493.
48. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR, (2004) Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 147: 123-126. doi:10.1016/j.jneuroim.2003.10.026. PubMed: 14741442.
49. Rock RB, Gekker G, Hu S, Sheng WS, Cabral GA, et al. (2007) WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J Neuroimmune Pharmacol 2: 178-183. doi:10.1007/s11481-006-9040-4. PubMed: 18040842.
50. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, et al. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49: 211-219. doi:10.1002/glia.20108. PubMed: 15390091.
51. Sheng WS, Hu S, Ni HT, Rock RB, Peterson PK, (2009) WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase. J Neuroimmune Pharmacol 4: 244-248. doi:10.1007/s11481-009-9147-5. PubMed: 19214751.
52. Dong JF, Detta A, Bakker MH, Hitchcock ER, (1993) Direct interaction with target-derived glia enhances survival but not differentiation of human fetal mesencephalic dopaminergic neurons. Neuroscience 56: 53-60. doi:10.1016/0306-4522(93)90561-S. PubMed: 8232917.
53. Silani V, Mariani D, Donato FM, Ghezzi C, Mazzucchelli F, et al. (1994) Development of dopaminergic neurons in the human mesencephalon and in vitro effects of basic fibroblast growth factor treatment. Exp Neurol 128: 59-76. doi:10.1006/exnr.1994.1113. PubMed: 7915238.
54. Liu B, Du L, Hong JS, (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293: 607-617. PubMed: 10773035.
55. Yang Z, Yang S, Qian SY, Hong JS, Kadiiska MB, et al. (2007) Cadmium-induced toxicity in rat primary mid-brain neuroglia cultures: role of oxidative stress from microglia. Toxicol Sci 98: 488-494. doi:10.1093/toxsci/kfm106. PubMed: 17483498.
56. Bennett BA, Rusyniak DE, Hollingsworth CK, (1995) HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 705: 168-176. doi:10.1016/0006-8993(95)01166-8. PubMed: 8821747.
57. Yao H, Allen JE, Zhu X, Callen S, Buch S, (2009) Cocaine and human immunodeficiency virus type 1 gp120 mediate neurotoxicity through overlapping signaling pathways. J Neurovirol 15: 164-175. doi:10.1080/13550280902755375. PubMed: 19319745.
58. Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I, (2006) Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 26: 6771-6780. doi:10.1523/JNEUROSCI.1054-06.2006. PubMed: 16793884.
59. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, et al. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (Suppl 1):: 345-358. doi:10.1016/j.neuropharm.2004.07.030. PubMed: 15464149.
60. Klein TW, Cabral GA, (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1: 50-64. doi:10.1007/s11481-005-9007-x. PubMed: 18040791.
61. Raborn ES, Cabral GA, (2010) Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor. J Pharmacol Exp Ther 333: 319-327. doi:10.1124/jpet.109.163055. PubMed: 20089805.
62. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, et al. (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49: 67-79. doi:10.1016/j.neuron.2005.11.027. PubMed: 16387640.
63. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A, (2003) Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41: 161-168. doi:10.1002/glia.10177. PubMed: 12509806.
64. Klegeris A, Bissonnette CJ, McGeer PL, (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139: 775-786. doi:10.1038/sj.bjp.0705304. PubMed: 12813001.
65. Walter L, Franklin A, Witting A, Wade C, Xie Y, et al. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23: 1398-1405. PubMed: 12598628.
66. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88. doi:10.1126/science.1088208. PubMed: 14526074.
67. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, et al. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995. PubMed: 10191316.
68. Shen M, Thayer SA, (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54: 459-462. PubMed: 9730904.
69. Chen Y, Buck J, (2000) Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism. J Pharmacol Exp Ther 293: 807-812. PubMed: 10869379.
70. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C, (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80: 448-456. doi:10.1046/j.0022-3042.2001.00716.x. PubMed: 11905991.
71. Shohami E, Mechoulam R, (2000) Dexanabinol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev Res 50: 211-215. doi:10.1002/1098-2299(200007/08)50:3/4.
72. Chung ES, Bok E, Chung YC, Baik HH, Jin BK, (2012) Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase. Brain Res 1451: 110-116. doi:10.1016/j.brainres.2012.02.058. PubMed: 22436849.
73. Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, et al. (2012) Effects of cannabinoids Delta(9)-tetrahydrocannabinol, Delta(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. Phytomedicine 19: 819-824. doi:10.1016/j.phymed.2012.04.002. PubMed: 22571976.
74. Kim HJ, Shin AH, Thayer SA, (2011) Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss. Mol Pharmacol 80: 357-366. doi:10.1124/mol.111.071647. PubMed: 21670103.
75. Mocchetti I, Nosheny RL, Tanda G, Ren K, Meyer EM, (2007) Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci 1122: 144-154. doi:10.1196/annals.1403.010. PubMed: 18077570.
76. Aksenov MY, Aksenova MV, Nath A, Ray PD, Mactutus CF, et al. (2006) Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 27: 217-228. doi:10.1016/j.neuro.2005.10.003. PubMed: 16386305.
77. Aksenov MY, Hasselrot U, Wu G, Nath A, Anderson C, et al. (2003) Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res 987: 1-9. doi:10.1016/S0006-8993(03)03194-9. PubMed: 14499939.
78. Minghetti L, Visentin S, Patrizio M, Franchini L, Ajmone-Cat MA, et al. (2004) Multiple actions of the human immunodeficiency virus type-1 Tat protein on microglial cell functions. Neurochem Res 29: 965-978. doi:10.1023/B:NERE.0000021241.90133.89. PubMed: 15139295.
79. Mollace V, Nottet HS, Clayette P, Turco MC, Muscoli C, et al. (2001) Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci 24: 411-416. doi:10.1016/S0166-2236(00)01819-1. PubMed: 11410272.
80. Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA, (2005) HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain. Res Rev 50: 14-26. doi:10.1016/j.brainresrev.2005.04.002.
81. Sheng WS, Hu S, Hegg CC, Thayer SA, Peterson PK, (2000) Activation of human microglial cells by HIV-1 gp41 and Tat proteins. Clin Immunol 96: 243-251. doi:10.1006/clim.2000.4905. PubMed: 10964543.
82. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, et al. (2006) Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 23: 109-119. doi:10.1016/j.nbd.2006.02.005. PubMed: 16697650.
83. Wallace DR, Dodson S, Nath A, Booze RM, (2006) Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59: 51-60. doi:10.1002/syn.20214. PubMed: 16237680.
84. Stella N, (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017-1030. doi:10.1002/glia.20983. PubMed: 20468046.
85. Visalli V, Muscoli C, Sacco I, Sculco F, Palma E, et al. (2007) N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction. BMC Neurosci 8: 106. doi:10.1186/1471-2202-8-S2-P106. PubMed: 18062818.
86. Yang Y, Yao H, Lu Y, Wang C, Buch S, (2010) Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PLOS ONE 5: e13427. doi:10.1371/journal.pone.0013427. PubMed: 20976166.
87. Block ML, Wu X, Pei Z, Li G, Wang T, et al. (2004) Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J 18: 1618-1620. PubMed: 15319363.
88. Gao HM, Liu B, Zhang W, Hong JS, (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 17: 1954-1956. PubMed: 12897068.
89. Choi SH, Lee da Y, Chung ES, Hong YB, Kim SU, et al. (2005) Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem 95: 1755-1765. doi:10.1111/j.1471-4159.2005.03503.x. PubMed: 16219027.
90. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, et al. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145-6150. doi:10.1073/pnas.0937239100. PubMed: 12721370.
91. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML, (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913. doi:10.1523/JNEUROSCI.4540-04.2005. PubMed: 15728830.
92. Lawson LJ, Perry VH, Dri P, Gordon S, (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39: 151-170. doi:10.1016/0306-4522(90)90229-W. PubMed: 2089275.
93. Auriault C, Joseph M, Tartar A, Bout D, Tonnel AB, et al. (1985) Regulatory role of a tripeptide (TKP) from the second constant domain of immunoglobulin G--I. Inhibition of rat and human macrophage activities. Int J Immunopharmacol 7: 73-79. doi:10.1016/0192-0561(85)90011-6. PubMed: 3158617.
94. Auriault C, Joseph M, Tartar A, Capron A, (1983) Characterization and synthesis of a macrophage inhibitory peptide from the second constant domain of human immunoglobulin G. FEBS Lett 153: 11-15. doi:10.1016/0014-5793(83)80109-4. PubMed: 6298003.
95. Rogove AD, Tsirka SE, (1998) Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 8: 19-25. doi:10.1016/S0959-440X(98)80005-5. PubMed: 9427623.
96. Thanos S, Mey J, Wild M, (1993) Treatment of the adult retina with microglia-suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in vivo and in vitro. J Neurosci 13: 455-466. PubMed: 7678855.
97. Rock RB, Hu S, Sheng WS, Peterson PK, (2006) Morphine stimulates CCL2 production by human neurons. J Neuroinflammation 3: 32. doi:10.1186/1742-2094-3-32. PubMed: 17156455.
98. Eugenin EA, Dyer G, Calderon TM, Berman JW, (2005) HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia 49: 501-510. doi:10.1002/glia.20137. PubMed: 15578658.
99. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, et al. (2006) CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 26: 1098-1106. doi:10.1523/JNEUROSCI.3863-05.2006. PubMed: 16436595.
100. Weiss JM, Downie SA, Lyman WD, Berman JW, (1998) Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J Immunol 161: 6896-6903. PubMed: 9862722.
101. Yao H, Yang Y, Kim KJ, Bethel-Brown C, Gong N, et al. (2010) Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 115: 4951-4962. doi:10.1182/blood-2010-01-266221. PubMed: 20354174.
102. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE, (1998) Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 44: 831-835. doi:10.1002/ana.410440521. PubMed: 9818943.
103. Mankowski JL, Queen SE, Clements JE, Zink MC, (2004) Cerebrospinal fluid markers that predict SIV CNS disease. J Neuroimmunol 157: 66-70. doi:10.1016/j.jneuroim.2004.08.031. PubMed: 15579282.
104. Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, et al. (2007) An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 64: 97-102. doi:10.1001/archneur.64.1.97. PubMed: 17210815.
105. Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, et al. (2001) Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis. J Infect Dis 184: 1015-1021. doi:10.1086/323478. PubMed: 11574916.
106. Becker Y, (2006) The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes-a review, hypothesis and implications for treatment. Virus Genes.
107. Combadière B, Faure S, Autran B, Debré P, Combadière C, (2003) The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS 17: 1279-1290. doi:10.1097/00002030-200306130-00002. PubMed: 12799549.
108. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, et al. (1998) Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 273: 23799-23804. doi:10.1074/jbc.273.37.23799. PubMed: 9726990.
109. Cotter R, Williams C, Ryan L, Erichsen D, Lopez A, et al. (2002) Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia. J Neurovirol 8: 585-598. doi:10.1080/13550280290100950. PubMed: 12476352.
110. Mizuno T, Kawanokuchi J, Numata K, Suzumura A, (2003) Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res 979: 65-70. doi:10.1016/S0006-8993(03)02867-1. PubMed: 12850572.
111. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU, (2002) Fractalkine and fractalkine receptors in human neurons and glial cells. J Neurosci Res 69: 418-426. doi:10.1002/jnr.10304. PubMed: 12125082.
112. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB, (1999) Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 163: 1628-1635. PubMed: 10415068.
113. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, et al. (2001) Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett 303: 132-136. doi:10.1016/S0304-3940(01)01699-8. PubMed: 11311510.
114. Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, et al. (2003) Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol 138: 144-155. doi:10.1016/S0165-5728(03)00117-6. PubMed: 12742664.
115. Tong N, Perry SW, Zhang Q, James HJ, Guo H, et al. (2000) Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol 164: 1333-1339. PubMed: 10640747.
116. Williams R, Yao H, Peng F, Yang Y, Bethel-Brown C, et al. (2010) Cooperative induction of CXCL10 involves NADPH oxidase: Implications for HIV dementia. Glia 58: 611-621. PubMed: 19941336.
117. Mehla R, Bivalkar-Mehla S, Nagarkatti M, Chauhan A, (2012) Programming of neurotoxic cofactor CXCL-10 in HIV-1-associated dementia: abrogation of CXCL-10-induced neuro-glial toxicity in vitro by PKC activator. J Neuroinflammation 9: 239. doi:10.1186/1742-2094-9-239. PubMed: 23078780.
118. Fernández-López D, Faustino J, Derugin N, Wendland M, Lizasoain I, et al. (2012) Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience 207: 307-315. doi:10.1016/j.neuroscience.2012.01.008. PubMed: 22285309.
119. Fraga D, Raborn ES, Ferreira GA, Cabral GA, (2011) Cannabinoids inhibit migration of microglial-like cells to the HIV protein Tat. J Neuroimmune Pharmacol 6: 566-577. doi:10.1007/s11481-011-9291-6. PubMed: 21735070.
120. Nosheny RL, Ahmed F, Yakovlev A, Meyer EM, Ren K, et al. (2007) Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci 25: 2275-2284. doi:10.1111/j.1460-9568.2007.05506.x. PubMed: 17445226.
121. Nosheny RL, Bachis A, Aden SA, De Bernardi MA, Mocchetti I, (2006) Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra. J Neurobiol 66: 1311-1321. doi:10.1002/neu.20288. PubMed: 16967504.
122. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, et al. (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188-193. doi:10.1038/367188a0. PubMed: 8114918.
123. Santosuosso M, Righi E, Lindstrom V, Leblanc PR, Poznansky MC, (2009) HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection. J Infect Dis 200: 1050-1053. doi:10.1086/605695. PubMed: 19698075.
124. Banisadr G, Fontanges P, Haour F, Kitabgi P, Rostène W, et al. (2002) Neuroanatomical distribution of CXCR4 in adult rat brain and its localization in cholinergic and dopaminergic neurons. Eur J Neurosci 16: 1661-1671. doi:10.1046/j.1460-9568.2002.02237.x. PubMed: 12431218.
125. Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, et al. (1996) kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A 93: 8051-8056. doi:10.1073/pnas.93.15.8051. PubMed: 8755601.
126. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, et al. (1998) Cytokine regulation of human microglial cell IL-8 production. J Immunol 160: 1944-1948. PubMed: 9469457.
127. Hu S, Sheng WS, Lokensgard JR, Peterson PK, (2005) Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 191: 886-889. doi:10.1086/427830. PubMed: 15717263.
128. Chao CC, Hu S, Tsang M, Weatherbee J, Molitor TW, et al. (1992) Effects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity. Implications in neuronal injury. J Clin Invest 90: 1786-1793. doi:10.1172/JCI116053. PubMed: 1358919.
129. Hu S, Cheeran MC, Sheng WS, Ni HT, Lokensgard JR, et al. (2006) Cocaine alters proliferation, migration, and differentiation of human fetal brain-derived neural precursor cells. J Pharmacol Exp Ther 318: 1280-1286. doi:10.1124/jpet.106.103853. PubMed: 16766721.
130. Chao CC, Gekker G, Sheng WS, Hu S, Tsang M, et al. (1994) Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther 269: 198-203. PubMed: 8169825.